TRML
Payout Frequency

Dividend History

Pay DateAmountEx-DateRecord Date
October 20, 2023$1.512023-10-202023-10-16

Dividends Summary

Company News

Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
GlobeNewswire Inc. • Delveinsight • October 16, 2025

Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)
Benzinga • Juan Monteverde • September 15, 2025

Law firm Monteverde & Associates is investigating the proposed sale of Tourmaline Bio to Novartis, where shareholders will receive $48.00 per share, to determine if the transaction is fair.

Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Zacks Investment Research • Zacks Equity Research • March 15, 2024

Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Related Companies